ADVENTRX Pharmaceuticals Inc (Anx) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ruffian who wrote (264)	9/10/2007 4:48:59 PM
From: Keith Feral	of 418

Big blocks going off all afternnon. The bio equivalncy study for docetaxel is an absolute breakthrough. It gives them far more credibility for vinorelbine and docetaxel, which is a $2.2 billion drug. That's 4 times bigger than the generic market for Cofactor. At some point, the analysts are going to start tweaking their revenue models and changing their price targets. I think the big question is what the post partnerhsip estimates of the company will be. I figure $5 is a good estimate for current fundamentals without any partnerships. I think $15 to $20 could be a fair value for the company with all partnerships for Cofactor and Vinorelbine. God knows what the value would be with Docetaxel and all the other bioequivalence drugs. Only 3 weeks left to wait until the end of September. By then, the company will be releasing phase 2 b data. As long as we don't get a negative surprise, the next 18 months are going to be a shitload of fun.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next